Evidence map›Paper›PMID 37150760›Full record

ArticleSurgical case reports2023

Long-term survival with nivolumab followed by irinotecan after total gastrectomy in alpha-fetoprotein-producing gastric cancer: a case report and review of the literature.

Takayo Ota, Katsuya Sakashita, Ryugo Sawada, Kurumi Seki, Hiroyuki Maeda, Noriko Tanaka, Toshimasa Tsujinaka

Open access · goldAbstract read
In one paragraph

Article in Surgical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takayo OtaDepartment of Medical Oncology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan. takayo.ota@gmail.com.ORCID http://orcid.org/0000-0003-1630-8301
Katsuya SakashitaDepartment of Surgery, Izumi City General Hospital, Izumi, Osaka, 594-0073, Japan.
Ryugo SawadaDepartment of Surgery, Izumi City General Hospital, Izumi, Osaka, 594-0073, Japan.
Kurumi SekiDepartment of Pathology, Izumi City General Hospital, Izumi, Osaka, 594-0073, Japan.
Hiroyuki MaedaDepartment of Radiology, Izumi City General Hospital, Izumi, Osaka, 594-0073, Japan.
Noriko TanakaDepartment of Radiology, Izumi City General Hospital, Izumi, Osaka, 594-0073, Japan.
Toshimasa TsujinakaDepartment of Surgery, Izumi City General Hospital, Izumi, Osaka, 594-0073, Japan.
Izumi City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlpha-fetoprotein-producing gastric cancer (AFPGC) is a rare type of aggressive gastric cancer (GC) with a dismal prognosis. We present a patient with AFPGC who achieved long-term survival through a multidisciplinary approach. CASE PRESENTATION: A 67-year-old man with advanced GC was referred to our hospital for systemic chemotherapy. He was diagnosed with cStage IVB AFPGC. During 2nd-line treatment, we could not control bleeding from the GC itself. After complete resection, during chemotherapy, portal venous tumor thrombi (PVTTs) and liver metastases were identified. With nivolumab followed by irinotecan, the PVTTs and liver metastases disappeared. Without immunotherapy and chemotherapy for 23 months, the patient has survived for 48 months so far with no recurrence of GC.

conclusionLong-term survival with AFPGC can be accomplished by using several different approaches, such as surgery, immunotherapy, and chemotherapy.

Indexed as

Alpha-fetoproteinGastric cancerLong-term survivalMultidisciplinary therapy

Identifiers

PMID37150760
PMCPMC10164665
OpenAlexW4375856098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.